The state of Missouri currently has 342 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02302742
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
All
Ages:
All
Trial Updated:
05/08/2023
Locations: Centerpoint Regional Medical Center, Independence, Missouri +5 locations
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Register for Updates
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Cancer Center - North Kansas City Hospital, Kansas City, Missouri +2 locations
Conditions: Breast Cancer
Register for Updates
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
NCT04106492
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Cancer
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Missouri Baptist Medical Center, Saint Louis, Missouri
Conditions: Colorectal Cancer
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Missouri Health Care, Columbia, Missouri
Conditions: Breast Cancer
Register for Updates
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
NCT05025735
Recruiting
This will be a single arm, open label pilot to test the combination of dapagliflozin, a commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in patients with HR+/HER2- mBC. The objective of this study is to determine if the addition of dapagliflozin to the combination of alpelisib and fulvestrant leads to significant reduction in all-grade hyperglycemia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Saint Luke's Cancer Institute, Kansas City, Missouri
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
Register for Updates